Moderna, Inc. (MRNA) bonds
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)
Close on Nov 17, 2026Market cap $82.56BP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$591.00M
Long-term debt
Net debt
-$1.13B
After $1.72B of cash
Implied interest rate
–
FY2025 interest ÷ average debt
Interest coverage
–
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Notes and loans outstanding
As tagged in Moderna's 10-Q for the period ended Jun 30, 2026
Moderna's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Drawn |
|---|---|---|
| (DDTL)-1 | $400.00M | – |
| (DDTL)-2 | $500.00M | – |
| Delayed Draw Term Loan | $900.00M | – |
| Initial Term Loan | $600.00M | $591.00M |
| Secured Debt | $1.50B | – |
See a number that looks wrong?